You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This book provides an introduction to the principles of pharmacogenomics and precision medicine, followed by the pharmacogenomics aspects of major therapeutic areas such as cardiovascular disease, cancer, organ transplantation, psychiatry, infection, antithrombotic drugs. It also includes genotyping technology and therapeutic drug monitoring in Pharmacogenomics; ethical, Legal and Regulatory Issues; cost-effectiveness of pharmacogenetics-guided treatment; application of pharmacogenomics in drug discovery and development and clinical Implementation of Pharmacogenomics for Personalized Precision Medicine. The contributors of Pharmacogenomics in Precision Medicine come from a team of experts, including professors from academic institutions and practitioner from hospital. It will give an in-depth overview of the current state of pharmacogenomics in drug therapy for all health care professionals and graduate students in the era of precision medicine.
Precision medicine, or personalized medicine, is related to treatment based on the patient’s individual characteristics. To promote this personalized approach, diseases must accurately be diagnosed; specific biomarkers can predict disease evolution and optimize therapy based on each patient's characteristics such as their genetic background, lifestyle and environmental risk factors. Over the years, we have seen a revolution in pharmacotherapy and management of patients receiving personalized medicine, especially when we consider immunotherapy and specific tyrosine kinases inhibitors. Patients with inflammatory diseases, such as monogenetic diabetes and chronic kidney disease, have benefited from the progress made within the last decade related to our understanding of the genetic basis of diabetes. Similarly, patients in precision oncology, with breast, prostate and blood cancer have experienced better overall survival rates with targeted therapy such as trastuzumab (breast cancer), PARPs inhibitors (prostate cancer), imatinib, ibrutinib and venetoclax (leukemia).
Treating China's Cultural Revolution as much more than a political event, this innovative volume explores its ideological dimensions. The contributors focus especially on the CR's discourse of heroism and messianism and its demonization of the enemy as reflected in political practice, official literature, and propaganda art, arguing that these characteristics can be traced back to hitherto-neglected undercurrents of Chinese tradition. Moreover, while most studies of the Cultural Revolution are content to point to the discredited cult of heroism and messianism, this book also explores the alternative discourses that have flourished to fill the resulting vacuum. The contributors analyze the intense intellectual and artistic ferment in post-Mao China that embody resistance to CR ideology, as well as the urgent quest for authentic individuality, new forms of social cohesion, and historical truth. Contributions by: Anne-Marie Brady, Woei Lien Chong, Lowell Dittmer, Monika Gaenssbauer, Nick Knight, Stefan R. Landsberger, Nora Sausmikat, Barend J. ter Haar, Natascha Vittinghoff, and Lan Yang.
None
本书目收录了海内外出版的以汉语为研究对象的专著与论文,收录的时间跨度从20世纪80年代至90年代。本书目的出版祢补了1982年以来汉语语言学研究书目的空白,是该研究领域治学和研究的有用工具。
An excellent guide for understanding the trends, challenges and opportunities facing China through globalization, this Handbook answers the pertinent questions regarding the globalization process and China’s influence on the world.